FGF 23 and Osteoprotegerin but not Fetuin A are associated with death and enhance risk prediction in non dialysis chronic kidney disease stages 3 5.
Numerous biomarkers have been shown to associate with clinical endpoints in chronic kidney disease (CKD) There is limited evidence whether biomarkers improve risk prediction in relation to clinical outcomes. Our study investigates whether a small suite of key chronic kidney disease mineral and bone disorder biomarkers could be used to enhance risk assessment in CKD.
Nephrology